These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

489 related items for PubMed ID: 18457527

  • 1. FTY720 (fingolimod) for relapsing multiple sclerosis.
    Horga A, Montalban X.
    Expert Rev Neurother; 2008 May; 8(5):699-714. PubMed ID: 18457527
    [Abstract] [Full Text] [Related]

  • 2. Fingolimod for the treatment of relapsing multiple sclerosis.
    Jeffery DR, Markowitz CE, Reder AT, Weinstock-Guttman B, Tobias K.
    Expert Rev Neurother; 2011 Feb; 11(2):165-83. PubMed ID: 21158700
    [Abstract] [Full Text] [Related]

  • 3. Differential effects of fingolimod (FTY720) on immune cells in the CSF and blood of patients with MS.
    Kowarik MC, Pellkofer HL, Cepok S, Korn T, Kümpfel T, Buck D, Hohlfeld R, Berthele A, Hemmer B.
    Neurology; 2011 Apr 05; 76(14):1214-21. PubMed ID: 21464424
    [Abstract] [Full Text] [Related]

  • 4. Fingolimod for relapsing multiple sclerosis: an update.
    Horga A, Castilló J, Montalban X.
    Expert Opin Pharmacother; 2010 May 05; 11(7):1183-96. PubMed ID: 20367536
    [Abstract] [Full Text] [Related]

  • 5. Fingolimod: a novel immunosuppressant for multiple sclerosis.
    Brown BA, Kantesaria PP, McDevitt LM.
    Ann Pharmacother; 2007 Oct 05; 41(10):1660-8. PubMed ID: 17785617
    [Abstract] [Full Text] [Related]

  • 6. Neurological S1P signaling as an emerging mechanism of action of oral FTY720 (fingolimod) in multiple sclerosis.
    Lee CW, Choi JW, Chun J.
    Arch Pharm Res; 2010 Oct 05; 33(10):1567-74. PubMed ID: 21052934
    [Abstract] [Full Text] [Related]

  • 7. Central nervous system-directed effects of FTY720 (fingolimod).
    Miron VE, Schubart A, Antel JP.
    J Neurol Sci; 2008 Nov 15; 274(1-2):13-7. PubMed ID: 18678377
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Assessment of the clinical and MRI results of the FREEDOMS and TRANSFORMS phase III. clinical trials].
    Jakab G.
    Ideggyogy Sz; 2012 May 30; 65(5-6):207-8. PubMed ID: 22724290
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
    Chiba K, Adachi K.
    Future Med Chem; 2012 Apr 30; 4(6):771-81. PubMed ID: 22530640
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.